title: Motivational disturbances and effects of L-dopa administration in neurofibromatosis-1 model mice.
abstract: Children with neurofibromatosis type 1 (NF1) frequently have cognitive and behavioral deficits. Some of these deficits have been successfully modeled in Nf1 genetically-engineered mice that develop optic gliomas (Nf1 OPG mice). In the current study, we show that abnormal motivational influences affect the behavior of Nf1 OPG mice, particularly with regard to their response to novel environmental stimuli. For example, Nf1 OPG mice made fewer spontaneous alternations in a Y-maze and fewer arm entries relative to WT controls. However, analysis of normalized alternation data demonstrated that these differences were not due to a spatial working memory deficit. Other reported behavioral results (e.g., open-field test, below) suggest that differential responses to novelty and/or other motivational influences may be more important determinants of these kinds of behavior than simple differences in locomotor activity/spontaneous movements. Importantly, normal long-term depression was observed in hippocampal slices from Nf1 OPG mice. Results from elevated plus maze testing showed that differences in exploratory activity between Nf1 OPG and WT control mice may be dependent on the environmental context (e.g., threatening or non-threatening) under which exploration is being measured. Nf1 OPG mice also exhibited decreased exploratory hole poking in a novel holeboard and showed abnormal olfactory preferences, although L-dopa (50 mg/kg) administration resolved the abnormal olfactory preference behaviors. Nf1 OPG mice displayed an attenuated response to a novel open field in terms of decreased ambulatory activity and rearing but only during the first 10 min of the session. Importantly, Nf1 OPG mice demonstrated investigative rearing deficits with regard to a novel hanging object suspended on one side of the field which were not rescued by L-dopa administration. Collectively, our results provide new data important for evaluating therapeutic treatments aimed at ameliorating NF1-associated cognitive/behavioral deficits.
authors.affiliation: Department of Psychiatry, Washington University School of Medicine, St. Louis, Missouri, United States of America. wozniakd@psychiatry.wustl.edu
authors.forename: David F
authors.initials: DF
authors.lastname: Wozniak
authors.forename: Kelly A
authors.initials: KA
authors.lastname: Diggs-Andrews
authors.forename: Sara
authors.initials: S
authors.lastname: Conyers
authors.forename: Carla M
authors.initials: CM
authors.lastname: Yuede
authors.forename: Joshua T
authors.initials: JT
authors.lastname: Dearborn
authors.forename: Jacquelyn A
authors.initials: JA
authors.lastname: Brown
authors.forename: Kazuhiro
authors.initials: K
authors.lastname: Tokuda
authors.forename: Yukitoshi
authors.initials: Y
authors.lastname: Izumi
authors.forename: Charles F
authors.initials: CF
authors.lastname: Zorumski
authors.forename: David H
authors.initials: DH
authors.lastname: Gutmann
mesh_terms: D000818:Animals; D001522:Behavior, Animal / Q000187:drug effects*; D003863:Depression / Q000175:diagnosis / Q000188:drug therapy / Q000209:etiology; D004195:Disease Models, Animal; D015259:Dopamine Agents / Q000008:administration & dosage*; D004594:Electrophysiology; D005260:Female; D006801:Humans; D019426:Integrases / Q000378:metabolism; D007980:Levodopa / Q000008:administration & dosage*; D008297:Male; D018782:Maze Learning / Q000187:drug effects; D008569:Memory Disorders / Q000175:diagnosis / Q000188:drug therapy / Q000209:etiology; D051379:Mice; D018345:Mice, Knockout; D008822:Mice, Transgenic; D009042:Motivation / Q000187:drug effects*; D009456:Neurofibromatosis 1 / Q000150:complications / Q000188:drug therapy* / Q000378:metabolism; D025542:Neurofibromin 1 / Q000502:physiology*
chemical_list: D015259:Dopamine Agents; D025542:Neurofibromin 1; D007980:Levodopa; C045073:Cre recombinase; D019426:Integrases